Participants:0–17 years · 18–64 years · 65+ years
Substances:H-GLY-LYS-TYR-GLY-PHE-TYR-THR-HIS-VAL-PHE-ARG-LEU-LYS-LYS-TRP-ILE-GLN-LYS-VAL-ILE-ASP-GLN-PHE-GLY-GLU-OH
Sponsor:Xinnate AB

Contact Research Centre

Colorectal cancer

Recruiting

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:Janssen Cilag International

Contact Research Centre

Plasma cell leukaemia

Recruiting

Study on the Safety and Effectiveness of ARI0002h and Drug Combination for Newly Diagnosed Primary Plasma Cell Leukemia Patients

Registered drugNo placebo

Study on the Safety and Effectiveness of ARI0002h and Drug Combination for Newly Diagnosed Primary Plasma Cell Leukemia Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Contact Research Centre

Still's disease+1

Recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis

Investigational

Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis

Investigational

Spain

Participants:0–17 years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Sickle cell disease

Recruiting

Study on How Well Etavopivat Works for Adolescents and Adults with Sickle Cell Disease

Investigational

Study on How Well Etavopivat Works for Adolescents and Adults with Sickle Cell Disease

Investigational

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Etavopivat
Sponsor:Novo Nordisk A/S

Contact Research Centre

Small cell lung cancer

Recruiting

Study on MK-6070 and Ifinatamab Deruxtecan for Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo

Study on MK-6070 and Ifinatamab Deruxtecan for Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Barcelona

What the registry says about research in the country

01 Neurodegenerative Research

Innovative studies focusing on Alzheimer's Disease and Frontotemporal Dementia, utilizing advanced brain imaging techniques to track disease progression and evaluate new therapeutic approaches.

Cerebral tau aggregates assessment
Amyloid deposition tracking
Progressive supranuclear palsy research

Advanced neuroimaging studies using PET tracers to understand disease mechanisms.

02 Infectious Disease Prevention

Comprehensive vaccine trials targeting various infections including Respiratory Syncytial Virus, Cytomegalovirus, and Herpes Zoster.

RSV vaccine development for older adults
CMV prevention studies
COVID-19 booster research

Focus on developing effective immunization strategies for vulnerable populations.

03 Metabolic and Chronic Conditions

Research examining treatments for Type 1 Diabetes and obesity, alongside studies in bladder cancer and urinary tract infections.

Diabetes management therapies
Cancer immunotherapy trials
UTI vaccine development

Innovative approaches to chronic disease management and prevention.

Back to Spain All countries